Outcome of Board Meeting to considered and approve An-audited Financials Results of Company for the Quarter ended 30th June 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Kapil Cotex Limited approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 at its meeting on August 14, 2025. Consolidated total income stood at ₹242.28 lakhs, but the company slipped into a loss after tax of ₹(1.87) lakhs versus a profit of ₹25.44 lakhs in the year-ago quarter. Note that Q1 FY25 was standalone-only because the subsidiary, Skybiotech Life Sciences Pvt Ltd, was acquired only from July 1, 2024, so year-on-year consolidated figures are not directly comparable. On a standalone basis, total income fell sharply to ₹2.96 lakhs from ₹35.42 lakhs in Q1 FY25, and the company posted a pre-tax loss of ₹(1.49) lakhs. Statutory auditor SPD & Associates issued an unmodified limited review report on both sets of results. Consolidated EPS for the quarter was ₹0.25.
Despite the small absolute size of the numbers, the swing to a consolidated loss from a profit a year ago is a negative signal. Standalone operations have visibly weakened. Investors should watch whether the Skybiotech subsidiary can drive sustained revenue and turn the group profitable going forward.